Most CRO playbooks assume you can ship a headline test on Tuesday and read results by Friday. Medical-Legal-Review does not work on that clock. We build landing page programs designed for the approval gate you actually have, not the one growth blogs assume you have.
The Problem
MLR turns testing cadence into a bottleneck
A standard growth team ships a new headline variant in an afternoon. In pharma, that same variant needs Medical, Legal, and Regulatory sign-off before it can go live, which can take days or weeks depending on your review cycle. Most agencies design test plans assuming weekly iteration, then watch the whole roadmap stall the first time MLR sends a page back with redlines. The fix isn't faster testing. It's fewer, higher-conviction tests submitted in batches that survive review the first time.
Fair Balance gets bolted on after the page is designed
Risk information has to appear with prominence comparable to benefit claims on any promotional page, not buried in a footer or a collapsed accordion. Teams routinely design the hero, the CTA, and the visual hierarchy first, then hand the page to Regulatory to 'add the safety info,' which forces last-minute layout surgery or an outright rejection. Fair Balance has to be a design constraint from wireframe one, not a compliance patch at the end.
One page is being asked to serve two audiences that need separate experiences
A physician evaluating mechanism of action, dosing, and clinical trial data has a different decision process than a patient trying to understand if a treatment applies to them. Serving both audiences the same landing page means either the clinical depth overwhelms the patient or the simplified patient framing under-serves the HCP. FDA guidance expects segmented experiences, and conversion suffers when a single generic page tries to do both jobs badly.
ISI placement and branded vs. unbranded rules constrain the exact tactics that drive lift elsewhere
Important Safety Information placement requirements dictate where risk content sits relative to the fold, and whether a page is disease-awareness (unbranded) or product-specific (branded) changes what claims, imagery, and CTAs are even permissible. Growth tactics that work in SaaS, like aggressive above-the-fold CTAs or benefit-only hero copy, are often non-compliant here. Teams that don't design around these constraints end up either non-compliant or so conservative the page never gets tested at all.
How We Help
We start with an audit of your current landing page inventory against three lenses at once: conversion performance, Fair Balance compliance, and MLR review history. Most teams have never looked at these three together, so the audit alone usually surfaces pages that are both underperforming and sitting closer to a compliance risk than anyone realized.
From there we build a test roadmap sized to your actual MLR cycle time, not a generic sprint calendar. If your review board turns submissions around in two weeks, we build two-week test batches with three to five variants bundled into a single submission package, each with the rationale MLR needs to approve or reject quickly. This is the single biggest lever in regulated CRO: reducing round-trips between growth and review, not trying to eliminate review.
On execution, every variant we design treats Fair Balance and ISI placement as inputs, not afterthoughts. We build layouts where risk information carries visual weight matched to the benefit claims next to it, and where the ISI sits at the placement your regulatory team has approved as standard, so new tests inherit compliance instead of re-litigating it each time. For HCP and patient audiences on the same product or condition, we build genuinely separate page experiences with distinct information architecture, not a shared template with swapped headlines.
We also work directly with your Medical, Legal, and Regulatory reviewers, not around them. We build a submission format that gives MLR what they need in one pass: the hypothesis, the specific copy or layout change, the Fair Balance treatment, and the audience segment. Reviewers who get organized, complete submissions approve faster than reviewers fielding scattered one-off requests, and that turnaround time is what determines how many tests you actually run in a quarter.
Measurement is built to isolate what a compliant test can actually tell you. Because you can't run five simultaneous variants the way a consumer brand might, we design sequential or holdout-based tests that produce a clean read with fewer concurrent variants, and we track HCP and patient funnels separately since they convert on different signals and different timelines.
Throughout, our differentiation is that we are not a general CRO shop that treats pharma as a vertical with extra paperwork. We build the compliance constraints into the strategy layer before a single wireframe exists, which is why our test plans survive MLR on the first submission far more often than plans built the other way around.
The output is a landing page system your commercial team can keep iterating on after we hand it off: templates that already carry Fair Balance and ISI placement correctly, a submission process MLR trusts, and a backlog of pre-vetted test ideas sized to your real review cadence.
What we deliver
- Landing page audit scored on conversion, Fair Balance compliance, and MLR history
- Page classification map: branded vs. unbranded, HCP vs. patient, by product and indication
- MLR-cadence-sized test roadmap with batched submission packages
- Compliant page templates with built-in Fair Balance treatment and approved ISI placement
- Separate HCP and patient page architectures where a single page was serving both
- MLR submission format designed to reduce review round-trips
- Segmented measurement plan tracking HCP and patient funnels independently
The pharma landing pages that win are not the ones that test fastest. They're the ones that get approved fastest, because in a regulated funnel, approval speed is conversion speed.
Our Methodology
We run a 90-day sprint structured around your actual MLR cycle rather than an arbitrary two-week cadence. Days 1-20 are the audit and classification phase: every page gets scored on performance, Fair Balance risk, and page-type accuracy, and we sit with your Regulatory and Medical reviewers to understand what has caused past rejections. This phase ends with a prioritized list of pages and a test roadmap paced to your real review turnaround, not a generic sprint calendar.
Days 21-60 are build and submission. We design test variants in batches sized to clear your MLR queue efficiently, with Fair Balance and ISI placement built in from the first draft rather than added after design. Each batch goes to your reviewers with a complete submission package so approval decisions can be made in one pass instead of several rounds of redlines.
Days 61-90 are live testing and handoff. Approved variants go live against segmented HCP and patient funnels, we read results against the compliant test design we built, and we hand your team a template library and submission process they can run without us. By day 90 you have a working test engine that fits inside your review structure instead of fighting it.
How We Work
The first 30 days are diagnostic: we audit your landing pages, sit with your MLR reviewers to understand rejection patterns, and classify every page by audience and regulatory category. You get a clear map of where conversion is being left on the table and where compliance risk is sitting quietly on live pages.
Days 31-60 are build. We design and submit test batches sized to your actual review turnaround, with Fair Balance and ISI placement treated as design inputs. Our team works as an embedded extension of your growth and regulatory functions, not a vendor dropping deliverables over a wall, which is what makes the MLR submission process actually run faster.
Days 61-90 are live testing, measurement, and handoff. We stand up segmented tracking for HCP and patient funnels, read results against the compliant design, and transfer the template library and submission process to your team so testing continues after the engagement ends.
Throughout, you have a single point of contact and a weekly cadence tied to your MLR review schedule, not an arbitrary sprint calendar. If your biotech or pharma company needs landing page optimization that survives Medical-Legal-Review instead of getting stalled by it, we should talk.
- Reduced MLR round-trips per test submission
- Higher first-pass approval rate on landing page variants
- Increased conversion on both HCP and patient-facing funnels
- Compliant Fair Balance and ISI treatment built into standard templates
- Clear separation of branded and unbranded page performance
- A repeatable test roadmap your team can run without outside help
If your biotech & pharma company needs landing page optimization leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How do you run A/B tests on a landing page when every change needs MLR approval?
We don't try to force a weekly testing cadence onto a review process that doesn't move that fast. Instead we batch three to five variants into a single MLR submission, sized to your actual review turnaround, so you get a full test cycle approved in one pass instead of submitting one change at a time.
What counts as Fair Balance on a landing page, and why does it matter for conversion design?
Fair Balance means risk information has to appear with prominence comparable to the benefit claims next to it, not in smaller text or a collapsed section below the fold. It matters for conversion design because it constrains hero layout, visual hierarchy, and CTA placement in ways generic CRO best practices ignore.
Do we need separate landing pages for physicians and patients?
In most cases, yes. HCP audiences typically need clinical trial data, mechanism of action, and dosing detail, while patient audiences need plain-language context about whether a treatment applies to them.
What is the difference between a branded and an unbranded landing page, and does it change what you can test?
An unbranded, disease-awareness page discusses a condition without naming a specific product, while a branded page promotes a named product and triggers full promotional requirements including Fair Balance and ISI. The tests permitted on each differ: unbranded pages have more flexibility on educational content, while branded pages carry stricter constraints on claims and layout.
How long does it take to see results from a landing page optimization engagement?
Our engagement runs a 90-day structure: roughly the first 20-30 days for audit and classification, the next 30 for build and MLR submission, and the final 30 for live testing and handoff. Because test cycles depend on your specific MLR turnaround, some clients see live results sooner and others later, but by day 90 you have both live test data and a repeatable process your team owns.
Do you work with our in-house Medical, Legal, and Regulatory reviewers, or replace that function?
We work directly with your existing MLR reviewers. We don't replace regulatory review or make compliance determinations ourselves.
